Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.70 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.70 |
| ▸ | MMP2 | P08253 | 2/20 | 0.68 |
| ▸ | MMP9 | P14780 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.64 |
| ▸ | LMNA | P02545 | 6/20 | 0.64 |
| ▸ | HTT | P42858 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 4/20 | 0.63 |
| ▸ | USP2 | O75604 | 3/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5327074 | 0.91 | KDM4E (0.67) | ALOX15CYP1A2CYP2D6HIF1AMMP2 | |
| SCHEMBL2518549 | 0.85 | ALOX15 (0.89) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| SCHEMBL2514842 | 0.82 | ALOX15 (1.00) | ALOX15CYP1A2CYP2D6HIF1AMMP2 | |
| SCHEMBL15217627 | 0.81 | KDM4E (0.68) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| Hydrochloric Acid SCHEMBL2516502 | 0.81 | ALOX15 (0.97) | ALOX15CYP1A2CYP2D6HIF1AMMP2 | |
| SCHEMBL112199 | 0.81 | MAOA (0.80) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| SCHEMBL17223775 | 0.80 | L3MBTL1 (0.58) | ALOX15CYP1A2CYP2D6HIF1AMMP2 | |
| SCHEMBL2521725 | 0.79 | ALOX15 (0.78) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| SCHEMBL9177673 | 0.79 | KDM4E (0.79) | ALOX15CYP1A2CYP2D6HIF1AKDM4E | |
| SCHEMBL1782934 | 0.79 | KDM4E (1.00) | ALOX15CYP1A2CYP2D6HIF1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324243-B2 | Derivatives of the aminated hydroxyquinoline class for treating cancers | BIOPHARMED (FR) | 2012-12-04 | — | — | US | claimed |
| US-20100120856-A1 | Derivatives of the Aminated Hydroxyquinoline Class For Treating Cancers | BIOPHARMED (FR) | 2010-05-13 | — | — | US | claimed |
| US-8614230-B2 | Derivatives of the aminated hydroxyquinoline class for treating cancers | BIOPHARMED (FR) | 2013-12-24 | — | — | US | disclosed |
| US-20130102630-A1 | Derivatives of the Aminated Hydroxyquinoline Class For Treating Cancers | BIOPHARMED (FR) | 2013-04-25 | — | — | US | disclosed |
| US-8324243-B2 | Derivatives of the aminated hydroxyquinoline class for treating cancers | BIOPHARMED (FR) | 2012-12-04 | — | — | US | disclosed |
| EP-2382193-A1 | PPAR AGONIST COMPOSITIONS AND METHODS OF USE | Biopharmed (FR) | 2011-11-02 | — | — | EP | disclosed |
| US-20110251238-A1 | PPAR AGONIST COMPOSITIONS AND METHODS OF USE | BIOPHARMED (FR) | 2011-10-13 | — | — | US | disclosed |
| WO-2010073235-A1 | PPAR AGONIST COMPOSITIONS AND METHODS OF USE | BIOPHARMED (FR) | 2010-07-01 | — | — | WO | disclosed |
| US-20100120856-A1 | Derivatives of the Aminated Hydroxyquinoline Class For Treating Cancers | BIOPHARMED (FR) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120856-A1 | Derivatives of the Aminated Hydroxyquinoline Class For Treating Cancers | HNMT, HRAS, NNMT | ALOX15 2737/4885CYP1A2 1405/4885CYP2D6 640/4885 |
| US-20130102630-A1 | Derivatives of the Aminated Hydroxyquinoline Class For Treating Cancers | HNMT, NQO1, NQO2 | ALOX15 1542/4885CYP1A2 1392/4885CYP2D6 841/4885 |
| US-20110251238-A1 | PPAR AGONIST COMPOSITIONS AND METHODS OF USE | PPARA, PPARG, PPARD | ALOX15 659/4885CYP1A2 737/4885CYP2D6 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.